TDC
MNTA

Thompson Davis & Co’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Thompson Davis & Co’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,000
Closed -$45K – 1208
2015
Q4 		$45K Hold
3,000
– – 0.06% 281
2015
Q3 		$49K Hold
3,000
– – 0.07% 268
2015
Q2 		$68K Buy
3,000
+1,000
+50% +$19.9K 0.08% 259
2015
Q1 		$30K Hold
2,000
– – 0.04% 425
2014
Q4 		$24K Buy
+2,000
New +$22.9K 0.03% 468

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Thompson Davis & Co's MNTA Position: Q1 2016 in Review

Thompson Davis & Co sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2016, closing a stake of 3,000 shares — an estimated $45K sold.

Thompson Davis & Co first reported a position in MNTA in Q4 2014 and held it in 5 quarters. The position peaked at $68K in Q2 2015. 148 funds tracked by Wall St. Rank hold MNTA as of Q1 2016.

  • Thompson Davis & Co reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 3,000 Momenta Pharmaceuticals, Inc. shares in Q1 2016, an estimated $45K.
  • Thompson Davis & Co first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2014 and held it in 5 quarters.
  • Thompson Davis & Co's Momenta Pharmaceuticals, Inc. position peaked at $68K in Q2 2015.
  • 148 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2016.

Based on Thompson Davis & Co's 13F filing for Q1 2016, filed 2 May 2016.